All articles by Bikrant Kumar Singh

  1. April’s top news stories

    I-Mab and MorphoSys begin Phase III study of blood cancer drug Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech…
    Read More…

    3 May
  2. March’s top news stories

    Aldeyra’s ALLEVIATE trial of reproxalap eyedrops meets endpoints Aldeyra Therapeutics reported positive data from the Phase III ALLEVIATE trial that…
    Read More…

    5 Apr
  3. February’s top news stories

    Eidos Therapeutics starts Phase III trial of AG10 in ATTR-CM Eidos Therapeutics commenced a pivotal Phase III clinical trial of…
    Read More…

    5 Mar
  4. January’s top news stories

    Janssen unblinds Phase III TITAN study for prostate cancer Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III…
    Read More…

    5 Feb
  5. Kolon TissueGene doses first subject in Phase III invossa trial

    Kolon TissueGene has dosed the first patient in a Phase III clinical trial evaluating invossa for the treatment of knee…
    Read More…

    26 Nov
  6. September’s top news stories

    EHP started enrolment in EHP-101 Phase I trial for MS and scleroderma Emerald Health Pharmaceuticals (EHP) started patient enrolment for…
    Read More…

    9 Oct
  7. HPTN reports positive data from HPTN 074 trial for HIV

    HIV Prevention Trials Network (HPTN) has reported positive results from the HPTN 074 trial, which evaluated an integrated intervention of…
    Read More…

    3 Sep
  8. August’s top news stories

    Gradalis commenced Phase lll trial of Vigil in Ewing’s sarcoma Gradalis started a Phase lll clinical trial of Vigil in…
    Read More…

    31 Aug
  9. July’s top news stories

    Kyoto University to begin trials of iPS cells to treat Parkinson’s Kyoto University’s Centre for iPS Cell Research and Application…
    Read More…

    6 Aug
  10. June’s top news stories

    Servier and Galapagos began ROCCELLA trial Servier and Galapagos commenced the ROCCELLA Phase 2 clinical trial to evaluate the efficacy…
    Read More…

    5 Jul

Go Top